Adaptimmune Therapeutics PLC — Director's Dealing 2016

Jun 23, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-06-23

Reporting Person: Duncan Barbara Gayle (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$1.48	2026-06-22	Ordinary Shares (332776)		Direct

Footnotes

F1: Exercisable as to 83,194 Ordinary Shares on June 23, 2017 and will be exercisable as to the remainder in monthly installments of 10,399 Ordinary Shares on the twenty-third of each month from July 23, 2017 through May 23, 2019, and in one installment of 10,405 Ordinary Shares on June 23, 2019.

F2: The exercise price was converted from GBP1.01 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.